Swiss pharma giant Novartis AG (NYSE:NVS) reported a second-quarter adjusted EPS of $1.97, up 21% year over year (+17% on constant currency), beating the consensus of $1.89. The company’s sales reached $12.51 billion, up 11% year over year and 9% in constant currency, beating the consensus of $12.375 billion. Also Read: FDA Approves Novartis’ Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors. Sales growth is driven by a strong performance from Entresto, Kesimpta, Cosentyx, Kisqali, Leqvio, and Pluvicto. The volume contributes 15 percentage points to growth. Generic competition had a negative impact of 2 percentage points, and ...